Severe Necrotizing Cutaneous Lesions Complicating Treatment with Interferon Beta-1b
- 8 June 1995
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 332 (23) , 1584-1585
- https://doi.org/10.1056/nejm199506083322316
Abstract
Recombinant interferon beta-1b (Betaseron) was licensed in 1993 to reduce exacerbations of multiple sclerosis. Approval of the drug was greeted enthusiastically, despite a modest 30 percent reduction in relapses and side effects that include local inflammatory reactions and a flulike syndrome.1 We report the occurrence of severe necrotizing cutaneous reactions in a 38-year-old woman with an eight-year history of multiple sclerosis. She self-injected the standard dose of recombinant interferon beta-1b (9 million units) subcutaneously on alternate days.Keywords
This publication has 3 references indexed in Scilit:
- Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosisNeurology, 1994
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Systemic alpha‐interferon therapy of multiple sclerosisNeurology, 1984